Asianet News English

'Lots of flaws': Bharat Biotech on vaccine immunogenicity responses report, says not peer-reviewed journal

It is based on data from 515 healthcare workers who received both doses of either of the two vaccines.

Lots of flaws Bharat Biotech on vaccine immunogenicity responses report, says not peer-reviewed journal-dnm
Author
Bengaluru, First Published Jun 9, 2021, 5:24 PM IST
  • Facebook
  • Twitter
  • Whatsapp

Hyderabad-based Bharat Biotech said that a study that compares the immune response of the two vaccines (Covishield and Covaxin) used in India is not peer-reviewed journal.

"A recent comparative report on evaluation of immunogenicity responses to spike protein after 1st and 2nd dose of Indian manufactured vaccines study had lots of flaws. The journal that stated comparative report said more antibodies produced by Covishield than Covaxin," Bharat Biotech said in a statement.

''It's not a peer-reviewed publication, nor statistically & scientifically designed study, the study design & conduct reflect an ad hoc analysis, rather than predetermined hypothesis. Further, the study was not registered on CTRI website, nor approved by CDSCO & SEC,'' the company further said.

It is based on data from 515 healthcare workers who received both doses of either of the two vaccines.

On Monday, Raches Ella, head of business development and advocacy at Bharat Biotech, questioned in tweets why "non-peer-reviewed work" was put out.

In a series of tweets, Ella responded to a media report, "Surprised that media/researchers are concluding based on non-peer-reviewed work. Limitation 1: Spike-based IgG's are not appropriate when evaluating Covaxin, which induces broad antibody responses to Spike, N, and M. Recommend live virus neutralization."

Recently, a pan-India study had claimed that Covishield vaccine produces more antibodies than Covaxin though both generate a “good immune response."

The yet-to-be-published study, posted on the preprint repository MedRxiv on June 4, covered 515 healthcare workers (HCW) — 305 men and 210 women — from 22 cities in 13 states.

Covishield, from the Oxford-AstraZeneca stable, is manufactured by the Serum Institute of India in Pune. Covaxin is the indigenously manufactured vaccine by Hyderabad-based Bharat Biotech in collaboration with ICMR and National Institute of Virology (NIV).

NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona 

Follow Us:
Download App:
  • android
  • ios